HRP20230477T1 - Spojevi i pripravci uree kao inhibitori smarca2/brm-atpaze - Google Patents
Spojevi i pripravci uree kao inhibitori smarca2/brm-atpaze Download PDFInfo
- Publication number
- HRP20230477T1 HRP20230477T1 HRP20230477TT HRP20230477T HRP20230477T1 HR P20230477 T1 HRP20230477 T1 HR P20230477T1 HR P20230477T T HRP20230477T T HR P20230477TT HR P20230477 T HRP20230477 T HR P20230477T HR P20230477 T1 HRP20230477 T1 HR P20230477T1
- Authority
- HR
- Croatia
- Prior art keywords
- carcinoma
- hydrogen
- cell
- cancer
- pharmaceutically acceptable
- Prior art date
Links
- 239000000362 adenosine triphosphatase inhibitor Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 150000003672 ureas Chemical class 0.000 title 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 10
- 239000001257 hydrogen Substances 0.000 claims 10
- 150000001875 compounds Chemical class 0.000 claims 9
- 150000003839 salts Chemical class 0.000 claims 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 3
- 125000000217 alkyl group Chemical group 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 150000002431 hydrogen Chemical class 0.000 claims 3
- 206010005003 Bladder cancer Diseases 0.000 claims 2
- 201000009030 Carcinoma Diseases 0.000 claims 2
- 208000030808 Clear cell renal carcinoma Diseases 0.000 claims 2
- 208000006168 Ewing Sarcoma Diseases 0.000 claims 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 2
- 101000702545 Homo sapiens Transcription activator BRG1 Proteins 0.000 claims 2
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 206010038389 Renal cancer Diseases 0.000 claims 2
- 208000008938 Rhabdoid tumor Diseases 0.000 claims 2
- 206010039491 Sarcoma Diseases 0.000 claims 2
- 102100031027 Transcription activator BRG1 Human genes 0.000 claims 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 2
- 239000013543 active substance Substances 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 2
- 229910052731 fluorine Inorganic materials 0.000 claims 2
- 239000011737 fluorine Substances 0.000 claims 2
- 208000005017 glioblastoma Diseases 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 2
- 210000001672 ovary Anatomy 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 201000010106 skin squamous cell carcinoma Diseases 0.000 claims 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 208000017897 Carcinoma of esophagus Diseases 0.000 claims 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 1
- 206010052360 Colorectal adenocarcinoma Diseases 0.000 claims 1
- 206010072449 Desmoplastic melanoma Diseases 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 201000005231 Epithelioid sarcoma Diseases 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 201000010915 Glioblastoma multiforme Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010023774 Large cell lung cancer Diseases 0.000 claims 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims 1
- 208000000172 Medulloblastoma Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 206010061872 Non-renal cell carcinoma of kidney Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010061332 Paraganglion neoplasm Diseases 0.000 claims 1
- 208000031839 Peripheral nerve sheath tumour malignant Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 208000033889 Renal medullary carcinoma Diseases 0.000 claims 1
- 206010073334 Rhabdoid tumour Diseases 0.000 claims 1
- 208000006938 Schwannomatosis Diseases 0.000 claims 1
- 208000036822 Small cell carcinoma of the ovary Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims 1
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 claims 1
- 201000000331 Testicular germ cell cancer Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 201000005969 Uveal melanoma Diseases 0.000 claims 1
- 208000002517 adenoid cystic carcinoma Diseases 0.000 claims 1
- 208000020990 adrenal cortex carcinoma Diseases 0.000 claims 1
- 208000007128 adrenocortical carcinoma Diseases 0.000 claims 1
- 239000000043 antiallergic agent Substances 0.000 claims 1
- 239000002111 antiemetic agent Substances 0.000 claims 1
- 229940125683 antiemetic agent Drugs 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 206010005084 bladder transitional cell carcinoma Diseases 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 208000019065 cervical carcinoma Diseases 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- 239000000460 chlorine Substances 0.000 claims 1
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 1
- 201000010240 chromophobe renal cell carcinoma Diseases 0.000 claims 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 1
- 206010073251 clear cell renal cell carcinoma Diseases 0.000 claims 1
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 claims 1
- 208000030381 cutaneous melanoma Diseases 0.000 claims 1
- 230000001120 cytoprotective effect Effects 0.000 claims 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000004202 endocervical carcinoma Diseases 0.000 claims 1
- 201000003914 endometrial carcinoma Diseases 0.000 claims 1
- 201000005619 esophageal carcinoma Diseases 0.000 claims 1
- 201000010175 gallbladder cancer Diseases 0.000 claims 1
- 201000007487 gallbladder carcinoma Diseases 0.000 claims 1
- 201000006585 gastric adenocarcinoma Diseases 0.000 claims 1
- 210000004602 germ cell Anatomy 0.000 claims 1
- 201000003911 head and neck carcinoma Diseases 0.000 claims 1
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims 1
- 230000000121 hypercalcemic effect Effects 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 229940121354 immunomodulator Drugs 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 208000020319 kidney medullary carcinoma Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 201000005249 lung adenocarcinoma Diseases 0.000 claims 1
- 201000009546 lung large cell carcinoma Diseases 0.000 claims 1
- 201000005243 lung squamous cell carcinoma Diseases 0.000 claims 1
- 208000019420 lymphoid neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000009020 malignant peripheral nerve sheath tumor Diseases 0.000 claims 1
- 206010027191 meningioma Diseases 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 201000005962 mycosis fungoides Diseases 0.000 claims 1
- 201000009494 neurilemmomatosis Diseases 0.000 claims 1
- 230000000955 neuroendocrine Effects 0.000 claims 1
- 208000029974 neurofibrosarcoma Diseases 0.000 claims 1
- 201000011330 nonpapillary renal cell carcinoma Diseases 0.000 claims 1
- 201000005292 ovarian small cell carcinoma Diseases 0.000 claims 1
- 229940124641 pain reliever Drugs 0.000 claims 1
- -1 pain relievers Substances 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 208000007312 paraganglioma Diseases 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 208000028591 pheochromocytoma Diseases 0.000 claims 1
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 claims 1
- 201000010174 renal carcinoma Diseases 0.000 claims 1
- 201000007416 salivary gland adenoid cystic carcinoma Diseases 0.000 claims 1
- 208000004548 serous cystadenocarcinoma Diseases 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 230000002381 testicular Effects 0.000 claims 1
- 208000008732 thymoma Diseases 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
- 201000005290 uterine carcinosarcoma Diseases 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Saccharide Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Steroid Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
Claims (10)
1. Spoj ili njegova farmaceutski prihvatljiva sol, naznačen time, da je predstavljen formulom I:
[image]
u kojoj:
R1 je odabran od vodika, amino i hidroksi-supstituiranog C1-2alkila;
R2 je vodik;
R3 je odabran od C1-2alkila i halogen-supstituiranog C1-2alkila;
R4 je vodik;
R5je odabran od vodika i halogena; i
R6 je odabran od vodika i halogena.
2. Spoj ili njegova farmaceutski prihvatljiva sol, prema patentnom zahtjevu 1, naznačen time, da:
R1je odabran od vodika, amino i hidroksi-metila;
R2 je vodik;
R3 je odabran od metila, difluorometila i trifluorometila;
R4 je vodik;
R5 je odabran od vodika, klora i fluora; i
R6 je odabran od vodika i fluora.
3. Spoj prema patentom zahtjevu 2 ili njegova farmaceutski prihvatljiva sol, naznačen time, da se bira od sljedećih:
[image]
4. Spoj prema patentnom zahtjevu 3, naznačen time, da ima strukturu
[image]
ili njegova farmaceutski prihvatljiva sol.
5. Farmaceutski pripravak, naznačen time, da sadrži spoj prema bilo kojem od patentnih zahtjeva 1 do 4 ili njegovu farmaceutski prihvatljivu sol, i jedan ili više farmaceutski prihvatljivih nosača.
6. Farmaceutska kombinacija, naznačena time, da sadrži spoj prema bilo kojem od patentnih zahtjeva 1 do 4 ili njegovu farmaceutski prihvatljivu sol, i jedno ili više terapeutski aktivnih sredstava.
7. Farmaceutska kombinacija prema patentnom zahtjevu 6, naznačena time, da se navedeno jedno ili više terapeutski aktivnih sredstava neovisno bira od sredstava protiv raka, sredstava protiv alergija, sredstava protiv povraćanja, sredstava za ublažavanje bolova, imunomodulatora i citozaštitnih sredstava.
8. Spoj prema bilo kojem od patentnih zahtjeva 1 do 4 ili njegova farmaceutski prihvatljiva sol, naznačen time, da je za uporabu kao lijek.
9. Spoj prema bilo kojem od patentnih zahtjeva 1 do 4 ili njegova farmaceutski prihvatljiva sol, naznačen time, da je za uporabu u liječenju poremećaja ili bolesti posredovanih s BRM i/ili BRG1, pri čemu poremećaj ili bolest posredovana s BRM i/ili BRG1 je solidan tumor, leukemija ili limfom.
10. Spoj za uporabu prema patentnom zahtjevu 9, naznačen time, da se navedeni poremećaj ili bolest bira od karcinoma pluća ne malih stanica, adenokarcinoma pluća, karcinoma pluća velikih stanica, karcinoma pluća ne malih stanica, karcinoma pluća pločastih stanica, raka pluća malih stanica, melanoma kože, dezmoplastičnog melanoma, melanoma uvee, karcinoma malih stanica jajnika (hiperkalcemični tip), rabdoidnog tumora jajnika, karcinoma pločastih stanica kože, glioma, karcinosarkoma maternice, karcinoma endometrija tijela maternice, seroznog cistadenokarcinoma jajnika, urotelnog karcinoma mokraćnog mjehura, primarnog limfoma središnjeg živčanog sustava, karcinoma jednjaka, raka mokraćnog mjehura, plazmacitoidne varijante raka mokraćnog mjehura, adenokarcinoma želuca, adenoidno cističnog karcinoma, limfoidne neoplazme, difuznog limfoma velikih B stanica, raka gušterače, kolorektalnog adenokarcinoma, kolangiokarcinoma, sarkoma, karcinoma glave i vrata, cervikalnih i endocervikalnih karcinoma, meduloblastoma, kožnog T-staničnog limfoma, hepatocelularnog karcinoma jetre, bubrežnog karcinoma papilarnih stanica, raka dojke, limfoma plaštenih stanica, karcinoma žučnog mjehura, karcinoma zametnih stanica testisa, svijetlostaničnog karcinoma bubrega, raka prostate, pedijatrijskog Ewingovog sarkoma, timoma, kromofobnog karcinoma bubrega, ne svijetlostaničnog karcinoma bubrega, feokromocitoma i paraganglioma, karcinoma štitnjače, malignog tumora ovojnice perifernog živca, neuroendokrinog karcinoma prostate, karcinoma pločastih stanica glave i vrata, adrenokortikalnog karcinoma, karcinoma pločastih stanica kože, raka zametnih stanica testisa, glioblastoma, multiformnog glioblastoma, Ewingovog sarkoma, svijetlostaničnog karcinoma bubrežnih stanica, neuroblastoma, difuznog limfoma velikih B stanica, akutne mijeloične leukemije, kronične limfocitne leukemije, multiplog mijeloma, malignih rabdoidnih tumora, epiteloidnih sarkoma, obiteljske švanomatoze, bubrežnih medularnih karcinoma, sinovijalnih karcinoma, i meningeoma.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862765138P | 2018-08-17 | 2018-08-17 | |
| EP19779145.2A EP3837256B1 (en) | 2018-08-17 | 2019-08-12 | Urea compounds and compositions as smarca2/brm-atpase inhibitors |
| PCT/IB2019/056847 WO2020035779A1 (en) | 2018-08-17 | 2019-08-12 | Urea compounds and compositions as smarca2/brm atpase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20230477T1 true HRP20230477T1 (hr) | 2023-07-21 |
Family
ID=68072895
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20230477TT HRP20230477T1 (hr) | 2018-08-17 | 2019-08-12 | Spojevi i pripravci uree kao inhibitori smarca2/brm-atpaze |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US11958846B2 (hr) |
| EP (2) | EP3837256B1 (hr) |
| JP (1) | JP7328323B2 (hr) |
| KR (1) | KR20210047313A (hr) |
| CN (2) | CN112585136B (hr) |
| AU (1) | AU2019322325B2 (hr) |
| BR (1) | BR112021002632A2 (hr) |
| CA (1) | CA3107097A1 (hr) |
| CY (1) | CY1126039T1 (hr) |
| DK (1) | DK3837256T3 (hr) |
| ES (1) | ES2946060T3 (hr) |
| FI (1) | FI3837256T3 (hr) |
| HR (1) | HRP20230477T1 (hr) |
| HU (1) | HUE061963T2 (hr) |
| LT (1) | LT3837256T (hr) |
| MX (1) | MX2021001804A (hr) |
| PL (1) | PL3837256T3 (hr) |
| PT (1) | PT3837256T (hr) |
| RS (1) | RS64238B1 (hr) |
| SI (1) | SI3837256T1 (hr) |
| WO (1) | WO2020035779A1 (hr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112153984A (zh) | 2018-01-30 | 2020-12-29 | 福宏治疗公司 | 化合物及其用途 |
| KR20220133258A (ko) | 2020-01-29 | 2022-10-04 | 포그혼 쎄라퓨틱스 인크. | 화합물 및 이의 용도 |
| CN112979646B (zh) * | 2021-03-08 | 2022-01-14 | 北京富龙康泰生物技术有限公司 | 一种咪唑并吡啶类衍生物 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2779780A (en) | 1955-03-01 | 1957-01-29 | Du Pont | 1, 4-diamino-2, 3-dicyano-1, 4-bis (substituted mercapto) butadienes and their preparation |
| AUPP003197A0 (en) | 1997-09-03 | 1997-11-20 | Fujisawa Pharmaceutical Co., Ltd. | New heterocyclic compounds |
| GB9823873D0 (en) | 1998-10-30 | 1998-12-30 | Pharmacia & Upjohn Spa | 2-ureido-thiazole derivatives,process for their preparation,and their use as antitumour agents |
| IL143236A0 (en) | 1998-12-16 | 2002-04-21 | Warner Lambert Co | Treatment of arthritis with mek inhibitors |
| US7217722B2 (en) * | 2000-02-01 | 2007-05-15 | Kirin Beer Kabushiki Kaisha | Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same |
| ES2461854T3 (es) | 2000-07-19 | 2014-05-21 | Warner-Lambert Company Llc | Ésteres oxigenados de ácidos 4-yodofenilamino-benzhidroxámicos |
| US20020173507A1 (en) | 2000-08-15 | 2002-11-21 | Vincent Santora | Urea compounds and methods of uses |
| RU2292344C2 (ru) | 2001-05-24 | 2007-01-27 | Лео Фарма А/С | Производные пиридилцианогуанидинов и фармацевтическая композиция на их основе |
| WO2003076424A1 (en) | 2002-03-08 | 2003-09-18 | Eisai Co. Ltd. | Macrocyclic compounds useful as pharmaceuticals |
| SI2130537T1 (sl) | 2002-03-13 | 2013-01-31 | Array Biopharma, Inc. | N3-alkilirani derivati benzimidazola kot inhibitorji mek |
| US20030236287A1 (en) | 2002-05-03 | 2003-12-25 | Piotrowski David W. | Positive allosteric modulators of the nicotinic acetylcholine receptor |
| MXPA05000130A (es) | 2002-06-27 | 2005-02-17 | Novo Nordisk As | Derivados de aril-carbonilo como agentes terapeuticos. |
| JP2007524596A (ja) | 2003-02-28 | 2007-08-30 | トランスフォーム・ファーマシューティカルズ・インコーポレイテッド | 共結晶医薬組成物 |
| WO2004085433A2 (en) | 2003-03-28 | 2004-10-07 | Pharmacia & Upjohn Company Llc | Positive allosteric modulators of the nicotinic acetylcholine receptor |
| PL1912636T3 (pl) | 2005-07-21 | 2015-02-27 | Ardea Biosciences Inc | N-(aryloamino)sulfonamidowe inhibitory mek |
| JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
| US8455513B2 (en) * | 2007-01-10 | 2013-06-04 | Aerie Pharmaceuticals, Inc. | 6-aminoisoquinoline compounds |
| ES2537352T3 (es) | 2007-09-12 | 2015-06-05 | Genentech, Inc. | Combinaciones de compuestos inhibidores de fosfoinositida 3-cinasa y agentes quimioterapéuticos, y metodos para su uso |
| WO2009055730A1 (en) | 2007-10-25 | 2009-04-30 | Genentech, Inc. | Process for making thienopyrimidine compounds |
| KR20100135255A (ko) | 2008-03-14 | 2010-12-24 | 오츠카 세이야쿠 가부시키가이샤 | Ｍｍｐ-2 및/또는 ｍｍｐ-9 저해제 |
| JP6665154B2 (ja) | 2014-07-17 | 2020-03-13 | ノース・アンド・サウス・ブラザー・ファーマシー・インベストメント・カンパニー・リミテッド | 置換尿素誘導体及びその薬学的使用 |
| MA41598A (fr) | 2015-02-25 | 2018-01-02 | Constellation Pharmaceuticals Inc | Composés thérapeutiques de pyridazine et leurs utilisations |
| CN105481723B (zh) | 2015-04-29 | 2017-08-25 | 中国农业大学 | 一种非均相催化的烷基/苄基/芳基脲类化合物的制备方法 |
| WO2018187414A1 (en) | 2017-04-05 | 2018-10-11 | The Regents Of The University Of California | Inhibitors of mtor-rictor interactions |
| WO2020126968A2 (en) | 2018-12-20 | 2020-06-25 | Bayer Aktiengesellschaft | Urea derivatives |
-
2019
- 2019-08-12 JP JP2021507613A patent/JP7328323B2/ja active Active
- 2019-08-12 HU HUE19779145A patent/HUE061963T2/hu unknown
- 2019-08-12 FI FIEP19779145.2T patent/FI3837256T3/fi active
- 2019-08-12 BR BR112021002632-0A patent/BR112021002632A2/pt unknown
- 2019-08-12 DK DK19779145.2T patent/DK3837256T3/da active
- 2019-08-12 US US17/268,512 patent/US11958846B2/en active Active
- 2019-08-12 PT PT197791452T patent/PT3837256T/pt unknown
- 2019-08-12 AU AU2019322325A patent/AU2019322325B2/en active Active
- 2019-08-12 CN CN201980054231.1A patent/CN112585136B/zh active Active
- 2019-08-12 KR KR1020217007586A patent/KR20210047313A/ko not_active Application Discontinuation
- 2019-08-12 LT LTEPPCT/IB2019/056847T patent/LT3837256T/lt unknown
- 2019-08-12 EP EP19779145.2A patent/EP3837256B1/en active Active
- 2019-08-12 HR HRP20230477TT patent/HRP20230477T1/hr unknown
- 2019-08-12 ES ES19779145T patent/ES2946060T3/es active Active
- 2019-08-12 MX MX2021001804A patent/MX2021001804A/es unknown
- 2019-08-12 CN CN202410736812.6A patent/CN118666832A/zh active Pending
- 2019-08-12 RS RS20230377A patent/RS64238B1/sr unknown
- 2019-08-12 CA CA3107097A patent/CA3107097A1/en active Pending
- 2019-08-12 SI SI201930542T patent/SI3837256T1/sl unknown
- 2019-08-12 EP EP23160099.0A patent/EP4219488A1/en active Pending
- 2019-08-12 PL PL19779145.2T patent/PL3837256T3/pl unknown
- 2019-08-12 WO PCT/IB2019/056847 patent/WO2020035779A1/en unknown
-
2023
- 2023-06-02 CY CY20231100266T patent/CY1126039T1/el unknown
-
2024
- 2024-03-12 US US18/602,126 patent/US20240270738A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| ES2946060T3 (es) | 2023-07-12 |
| CN112585136A (zh) | 2021-03-30 |
| CN112585136B (zh) | 2024-06-25 |
| KR20210047313A (ko) | 2021-04-29 |
| PT3837256T (pt) | 2023-05-23 |
| RS64238B1 (sr) | 2023-06-30 |
| EP3837256B1 (en) | 2023-03-08 |
| US20210323956A1 (en) | 2021-10-21 |
| EP3837256A1 (en) | 2021-06-23 |
| US20240270738A1 (en) | 2024-08-15 |
| SI3837256T1 (sl) | 2023-07-31 |
| LT3837256T (lt) | 2023-06-12 |
| FI3837256T3 (fi) | 2023-05-15 |
| CY1126039T1 (el) | 2023-11-15 |
| US11958846B2 (en) | 2024-04-16 |
| CN118666832A (zh) | 2024-09-20 |
| AU2019322325B2 (en) | 2022-01-20 |
| EP4219488A1 (en) | 2023-08-02 |
| CA3107097A1 (en) | 2020-02-20 |
| MX2021001804A (es) | 2021-04-19 |
| JP2021534147A (ja) | 2021-12-09 |
| BR112021002632A2 (pt) | 2021-05-11 |
| DK3837256T3 (da) | 2023-05-30 |
| PL3837256T3 (pl) | 2023-07-10 |
| HUE061963T2 (hu) | 2023-09-28 |
| WO2020035779A1 (en) | 2020-02-20 |
| AU2019322325A1 (en) | 2021-02-18 |
| JP7328323B2 (ja) | 2023-08-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20230477T1 (hr) | Spojevi i pripravci uree kao inhibitori smarca2/brm-atpaze | |
| JOP20190090B1 (ar) | مشتقات 9،8،7،6-رابع هيدرو-3h-بيرازولو [4،3-f]أيزوكينولين مفيدة في علاج السرطان | |
| IL283184B2 (en) | Crystal polymorph of (7s,13r)-11-fluoro-7,13-dimethyl-6,7,13,14-tetrahydro-1,15-ethenopyrazolo[4,3-f][1,4,8,10] benzoxatriazacyclotridecin–4(5h)–one for the treatment of cancer | |
| JP2012082234A5 (hr) | ||
| JP2019533981A5 (hr) | ||
| ZA202201329B (en) | Quinazolin-4-one derivatives useful for the treatment of braf-associated diseases and disorders | |
| EA201992418A1 (ru) | Бициклические соединения и их применение в лечении рака | |
| HRP20200696T1 (hr) | Terapija u kombinaciji s inhibitorom topoizomeraze | |
| JP2015096544A5 (hr) | ||
| EP3885344A3 (en) | Pyrimidine compounds, preparation method therefor and pharmaceutical uses thereof | |
| DOP2011000057A (es) | Compuestos de pirrolo-pirimidina como inhibidores de cdk | |
| BR112016027048A8 (pt) | uso de um composto de fórmula i no tratamento de câncer cerebral e glioblastoma multiforme mgmt positivo | |
| HRP20220375T1 (hr) | Kombinirana terapija inhibitorom bromodomenskog i ekstraterminalnog proteina | |
| JP2020536066A5 (hr) | ||
| JP2017514806A5 (hr) | ||
| NZ726365A (en) | Combinations for treating cancers | |
| RU2018102963A (ru) | Производные анилинпиримидина и их применения | |
| EA201791881A1 (ru) | Производные 2-аминопиридина в качестве антагонистов рецептора аденозина aи лигандов рецепторов мелатонина mt | |
| JP2014532751A5 (hr) | ||
| MX2023005295A (es) | Tratamiento contra el cancer resistente a platino. | |
| RU2010119922A (ru) | Усовершенствованное противоопухолевое лечение | |
| JP2014005265A5 (hr) | ||
| MX2021004885A (es) | Derivados de piperazinil y piperidinil-quinazolin-4(3h)-ona que tienen actividad contra el dolor. | |
| MX2018004868A (es) | Derivados de la pirrolidina. | |
| JPWO2020035779A5 (hr) |